Uses
DS-1001b is an orally active, blood-brain permeable, potent IDH-1 (isocitrate dehydrogenase-1) mutant inhibitor. DS-1001b has antitumor activity[1][2][3].
References
[1] Zhao Yizhaiteng, et al. Isoxazole derivative as mutated isocitrate dehydrogenase 1 inhibitor. WO2016052697A1.
[2] Nakagawa M, et al. Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma. Oncogene. 2019 Oct;38(42):6835-6849. DOI:
10.1038/s41388-019-0929-9[3] Matsunaga H, et al. Characterization of a novel BBB-permeable mutant IDH1 inhibitor, DS-1001b. Annals of Oncology, 2019, 30: v145-v146.
